Director, CMC Analytical
Liang joins Aceragen with chemistry, manufacturing and controls analytical and bioanalytical experiences in drug development for rare diseases. Previously, Liang worked at CRISPR Therapeutics, Homology Medicines and Tessera Therapeutics. He and his team developed analytical methods to characterize and quality control modalities, Cas9/gRNA, mRNA, lipid nanoparticles, virus and proteins.
He worked on LC/MS-MS assays, cell-based assays and analytical methods for LNP formulation. Liang is a graduate of the Chinese Academy of Sciences and NYU and is passionate about the scientific and technological aspects of process development.